Investigational drug · Phase 3
atropine sulfate eye drops
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Myopia, Myopia Progression.
Phase 3Last checked: Nov 20, 2026Latest source record: Jan 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
91
Any phase or sponsor naming "atropine sulfate eye drops"
First trial start
2022
Mar 15, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "atropine sulfate eye drops", any sponsor or status.
Conditions studied
As listed on its trial records.
- Myopia
- Myopia Progression
Largest trials
Live from ClinicalTrials.gov: studies naming "atropine sulfate eye drops" as an intervention, largest first.
- Efficacy of Different Interventions for Progressive Myopia After Orthokeratology Lens WearNot yet recruiting
Tianjin Medical University Eye HospitalAcademic, hospital or other
NCT07494799 · 3,890 participants (planned) · Start Apr 1, 2026 · Primary completion May 1, 2026
Drug: OK Lens + 0.01% Atropine Group · For: Progressive Myopia; Pediatric Myopia; Orthokeratology-related Myopia Progression
- The Safety and Efficacy of SYD-101 in Children With MyopiaPivotal-lookingCompleted
Sydnexis, Inc.Industry
NCT03918915 · 852 participants · Start Apr 24, 2019 · Primary completion May 2, 2024
Drug: SYD-101 0.01%; SYD-101 0.03% and 1 more · For: Nearsightedness; Near Sightedness; Near-sightedness
Sites: Irwindale, California; Pasadena, California; San Diego, California · 47 sites in all
- A Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye DropsPivotal-lookingActive, not recruiting
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.Industry
NCT06209320 · 777 participants (planned) · Start Mar 15, 2022 · Primary completion Mar 21, 2025
Drug: Lower dose atropine sulfate eye drops; Low dose atropine sulfate eye drops and 1 more · For: Myopia
Sites: Beijing, China
- Study of OT-101 in Treating MyopiaPivotal-lookingActive, not recruiting
Ocumension (Hong Kong) LimitedAcademic, hospital or other
NCT04770610 · 678 participants (planned) · Start Apr 1, 2021 · Primary completion Mar 2027
Drug: OT-101 Ophthalmic Solution; Vehicle · For: Myopia, Progressive
Sites: Colorado Springs, Colorado; Fort Collins, Colorado; Gainesville, Florida · 15 sites in all
- Delaying the Onset of Nearsightedness Until Treatment (DONUT) Clinical TrialPivotal-lookingRecruiting
Ohio State UniversityAcademic, hospital or other
NCT07567040 · 664 participants (planned) · Start May 27, 2026 · Primary completion May 15, 2028
Drug: Atropine Sulfate 0.05% Oph Soln; Placebo · For: Myopia
Sites: Birmingham, Alabama; Berkeley, California; Fullerton, California · 13 sites in all
- The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia ProgressionPivotal-lookingRecruiting
Oupushifang Pharmaceutical Technology Co., Ltd.Academic, hospital or other
NCT06708156 · 606 participants (planned) · Start Jun 15, 2024 · Primary completion Dec 31, 2026
Drug: Atropine sulfate eye drops 0.01%; Atropine sulfate eye drops 0.02% and 1 more · For: Myopia; Myopia Progression
Sites: Hefei, China; Xuancheng, China; Lanzhou, China · 25 sites in all
- Efficacy and Safety of Low-concentration Atropine for Myopia Control in Chinese Children and AdolescentsPivotal-lookingStatus unknown
Shanghai Eye Disease Prevention and Treatment CenterAcademic, hospital or other
NCT05597163 · 588 participants (planned) · Start Jan 15, 2023 · Primary completion Nov 1, 2024
Drug: low concentration atropine (0.01%); low concentration atropine (0.025%) and 2 more · For: Myopia, Progressive
- MAD Trial: Myopia Atropine DosePivotal-lookingActive, not recruiting
Erasmus Medical CenterAcademic, hospital or other
NCT05667454 · 550 participants (planned) · Start Dec 19, 2022 · Primary completion Apr 24, 2029
Drug: Atropine Ophthalmic 0.05%; Atropine Ophthalmic 0.5% · For: Progressive Myopia
Sites: Almere Stad, Netherlands; Amsterdam, Netherlands; Delft, Netherlands · 20 sites in all
- A Phase III Clinical Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye DropsPivotal-lookingActive, not recruiting
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.Industry
NCT06209281 · 526 participants · Start May 13, 2022 · Primary completion Aug 20, 2023
Drug: Lower dose atropine sulfate eye drops; Low dose atropine sulfate eye drops and 1 more · For: Myopia
Sites: Shanghai, China
- Early-Onset Myopia Intervention ProjectRecruiting
Shanghai Eye Disease Prevention and Treatment CenterAcademic, hospital or other
NCT07176949 · 508 participants (planned) · Start Jun 1, 2025 · Primary completion Jun 1, 2027
Drug: 0.01% atropine eye drops; 0.05% atropine eye drops · For: Myopia; Pre-myopia
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- A validated sensitive LC-MS/MS method and its application in elucidating the unique ocular pharmacokinetic profile of 0.01% atropine underpinning its clinical utility for myopia.
Yue J, Liu S, Zhou S, et al. · J Chromatogr B Analyt Technol Biomed Life Sci 2026
- A sea buckthorn seed oil nano-emulsion in the management of digital screen-induced ocular conditions.
Cheng M, Bi X, Zhao S, et al. · Eur J Pharm Biopharm 2026
- STudy of Atropine to Reduce (STAR) Myopia Progression in Children: 24-Month Results of a Randomized, Double-Masked, Vehicle-Controlled Trial of Atropine Sulfate 0.01% and 0.03.
Korenfeld M, Hurcikova M, Tatsuoka K, et al. · Ophthalmol Ther 2026
- Impact of atropine on changes in choroidal thickness in children with myopia: a meta-analysis of randomized controlled trials.
Liu LP, Tang Y, Zhang JN, et al. · Front Med (Lausanne) 2025
- Effect and safety assessment of low-concentration atropine eye drops on the growth and development of juvenile cynomolgus monkeys over a period of one year.
Guo J, Huang Y, Lin J, et al. · Technol Health Care 2025
- Juvenile toxicity of atropine sulfate eye drops in young rats.
Zhang W, Yang W, Liu L, et al. · Cutan Ocul Toxicol 2025
Also in development for Myopia
- Lower sulfate eye dropsLower sulfatePhase 32 trials
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. · Myopia
- CTO0308Phase 31 trial
Taejoon Pharmaceutical Co., Ltd. · Myopia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.